1. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease 
Fernando Sergio Leitao Filho, MD, PhD, Seung Won Ra, MD, PhD, Andre Mattman, MD, Robert S. Schellenberg, MD, Nick Fishbane, MSc, Gerard J. Criner, MD, Prescott G. Woodruff, MD, MPH, Stephen C. Lazarus, MD, Richard Albert, MD, John E. Connett, PhD, Meilan K. Han, MD, MSc, Fernando J. Martinez, MD, MSc, Janice M. Leung, MD, S.F. Paul Man, MD, Shawn D. Aaron, MD, Robert M. Reed, MD, Don D. Sin, MD, MPH 
Journal of Allergy and Clinical Immunology 
Volume 140, Issue 4, Pages e6 (October 2017)
DOI: /j.jaci
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Lower serum total IgG levels were associated with worse outcomes among participants with COPD in both cohorts (Q1, lowest quartile of total IgG levels; Q4, highest quartile of total IgG levels). A (MACRO) and B (STATCOPE), Rate of COPD exacerbations per person-year according to quartiles of serum total IgG. Error bars = 95% CI. C and E (MACRO) and D and F (STATCOPE), Participants with COPD exacerbations and hospitalizations during the study period according to quartiles of serum total IgG (log-rank test for trend: P < .001 for all quadrants). Log-rank test used for comparisons between Q1 and Q4.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig E1
Frequency of participants with COPD exacerbations, recurrent exacerbations (2 or more exacerbations), and hospitalizations during the study period across quartiles of serum total IgG levels in the derivation (MACRO) and validation (STATCOPE) cohorts (Q1, lowest quartile of total IgG levels; Q4, highest quartile of total IgG levels).
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig E2
Serum total IgG levels according to the number of exacerbations during the study period in the derivation (MACRO) and validation (STATCOPE) cohorts. MACRO: 9.7 ± 3.2 g/L for nonexacerbators vs 9.0 ± 3.0 g/L for 1 to 2 exacerbations/y vs 8.6 ± 3.4 g/L for 3 or more exacerbations/y (P for trend <.001). STATCOPE: 9.9 ± 3.1 g/L for those with no exacerbations; 9.3 ± 3.1 g/L for those with 1 or 2 exacerbations/y; and 8.6 ± 2.7 g/L for those with 3 or more exacerbations/y (P for trend <.001). *P < .05 for comparisons between groups (Kruskal-Wallis test with adjustments for multiple comparisons). Error bars represent 95% CI for the mean.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions